Retatrutide Tracking Considerations: Emerging Triple-Agonist Research
Retatrutide is an investigational triple agonist of GLP-1, GIP, and glucagon receptors. Here is how it differs from approved single and dual agonists, what it is (and is not) approved for, and the protocol-log variables a tracker captures — not a dose or a schedule, which are set by a trial protocol or prescriber.
What You'll Learn
- ✓Understand the receptor mechanism of retatrutide compared to single and dual agonists.
- ✓Identify the tracking variables most relevant to retatrutide research protocols.
- ✓Recognize the distinct side-effect timing pattern reported in early trials.
1. Direct Answer: A Triple Agonist Under Investigation
Retatrutide (LY3437943, Eli Lilly) is an investigational peptide that activates THREE incretin receptors: GLP-1 (like semaglutide), GIP (added by tirzepatide), and GLUCAGON (the new addition). The glucagon arm is the differentiating feature — it increases energy expenditure and lipolysis in addition to the satiety and glucose-control effects of the other two arms. Published Phase 2 trials reported mean weight loss of approximately 24% at 48 weeks at the highest dose tested — substantially higher than the ~15% reported for semaglutide and ~21% for tirzepatide in comparable trials. Retatrutide is NOT FDA approved as of this writing and remains in clinical trials. Research log tracking focuses on the schedule as set by the trial or prescriber, side-effect onset and resolution, weight trajectory, and any markers being personally monitored. This content is for educational and research-tracking purposes only and does not constitute medical advice.
Key Points
- •Retatrutide is a triple agonist (GLP-1 + GIP + glucagon).
- •Glucagon arm adds energy expenditure on top of satiety effects.
- •Phase 2 reported ~24% weight loss at 48 weeks; not FDA approved.
2. Mechanism Compared to Approved Agonists
SEMAGLUTIDE (Wegovy, Ozempic): GLP-1 agonist only. Slows gastric emptying, increases satiety, lowers glucose. Approved for type 2 diabetes and chronic weight management. Reported weight loss ~15% at 68 weeks. TIRZEPATIDE (Mounjaro, Zepbound): dual GLP-1 + GIP agonist. The GIP arm adds glucose-dependent insulinotropic effects and additional metabolic actions. Reported weight loss ~21% at 72 weeks. RETATRUTIDE: triple GLP-1 + GIP + GLUCAGON. The glucagon arm uniquely increases energy expenditure (so total energy balance favors weight loss even more), increases lipolysis, and improves liver fat in published trials. The glucagon agonism also adds heart-rate elevation as a side effect, slightly more than GLP-1 agonists alone. Each successive receptor addition has expanded the metabolic profile and the magnitude of effect — but also the breadth of potential side effects.
Key Points
- •Semaglutide: GLP-1 only.
- •Tirzepatide: GLP-1 + GIP.
- •Retatrutide: GLP-1 + GIP + glucagon — adds energy expenditure.
3. Why This Is Not a Protocol Guide
Retatrutide is investigational — it is in clinical trials and is not approved or available for use outside of them. There is no established outpatient dose or schedule, and this page deliberately does not provide one; trial dosing is set by the trial protocol and its investigators. If you are documenting any peptide protocol, Dosed logs the administrations, injection sites, reconstitution dates, weight, and notes you choose to record — it does not supply a dose, a schedule, or a monitoring plan. This content is for educational and tracking purposes only and does not constitute medical advice.
Key Points
- •Retatrutide is investigational and only available within clinical trials.
- •There is no approved outpatient dose or schedule — this page does not provide one.
- •Dosed documents a protocol; it does not design, dose, or monitor one.
4. Distinct Side-Effect Pattern
Retatrutide trials reported a side-effect profile similar to GLP-1 agonists with some unique additions from the glucagon arm. GI EFFECTS (nausea, vomiting, diarrhea, constipation): dose-dependent, peak in first 1-2 days post-injection, decline over 5-7 days at lower doses, persist longer at higher doses. SATIETY AND APPETITE SUPPRESSION: profound at higher doses, including reports of food aversion. HEART RATE: average increase of 4-10 bpm at higher doses, more pronounced than GLP-1-only agonists due to glucagon-driven sympathetic activation. RESTING ENERGY EXPENDITURE: increased meaningfully, contributing to the larger weight loss vs single or dual agonists. HEPATIC LIPID: significant reductions reported in trials, suggesting potential application in NASH and related conditions. INJECTION SITE: typical local reactions (redness, itching, sometimes small wheals) usually resolving in 24-72 hours. Researchers tracking their personal logs typically note onset time and severity on a 0-10 scale to inform dose-escalation pacing.
Key Points
- •GI effects similar to GLP-1 agonists, dose-dependent.
- •Heart-rate elevation more pronounced than with GLP-1-only agonists.
- •Resting energy expenditure increase is unique to the triple agonist mechanism.
5. Tracking Variables for Personal Research Logs
Researchers personally tracking retatrutide protocols typically maintain a structured log with the following variables: DATE AND TIME OF INJECTION, DOSE in mg, INJECTION SITE (quadrant tracking to avoid lipohypertrophy), CONCENTRATION of reconstituted peptide, RESEARCH BATCH IDENTIFIER. WEIGHT: same scale, same time of day, ideally morning post-void. WAIST CIRCUMFERENCE: weekly. RESTING HEART RATE: daily morning resting HR (taken in supine position before getting up). BLOOD PRESSURE: weekly. SIDE EFFECTS: onset, severity 0-10, duration in hours. SLEEP, ENERGY, APPETITE: 0-10 daily ratings. ANY LABS personally monitored. APP-BASED TRACKING reduces transcription error and produces graphical trends across the protocol period. This content is for educational and research-tracking purposes only.
Key Points
- •Structured log: dose, site, weight, vitals, side effects.
- •Resting morning HR is especially informative for triple agonists.
- •App-based tracking reduces error and produces trend visualizations.
6. Storage, Reconstitution, and Stability Considerations
Retatrutide research peptides are typically supplied as a lyophilized powder. Reconstitution with bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) preserves the peptide for approximately 28 days refrigerated 2-8°C, per general peptide stability principles — though specific manufacturer guidance should always be followed. Once reconstituted, mark the date on the vial. Lyophilized powder stored at -20°C or below in original packaging is stable for the labeled shelf life. Avoid freeze-thaw cycles after reconstitution. Light-sensitive peptides should be stored in opaque or amber vials. Any reconstitution volume or dose math depends on the specific product and the protocol it is used in, so this page does not provide dose-volume calculations. This content is for educational and research purposes only.
Key Points
- •Reconstituted peptide ~28 days refrigerated with bacteriostatic water.
- •Mark reconstitution date on vial; avoid freeze-thaw after reconstitution.
- •Reconstitution calculators reduce dose-math errors.
7. Using Dosed for Retatrutide Protocol Tracking
Dosed supports researcher-managed tracking of investigational peptide protocols including retatrutide. Log dose, injection site, weight, vitals, and side effects; the app produces trend visualizations, side-effect heat maps across the protocol period, and reconstitution calculators that match the peptide concentration to the target dose. Dose-escalation schedules can be templated based on published trial protocols. This content is for educational and research-tracking purposes only and does not constitute medical advice.
Key Points
- •Researcher-managed log of dose, site, weight, vitals, side effects.
- •Trend visualizations and side-effect heat maps across the protocol.
- •Reconstitution calculator for concentration-to-dose math.
Key Facts
- ★Retatrutide is a triple GLP-1 + GIP + glucagon agonist (Eli Lilly LY3437943).
- ★Phase 2 reported ~24% weight loss at 48 weeks at high dose.
- ★Glucagon arm uniquely increases energy expenditure.
- ★Heart-rate elevation more pronounced than GLP-1-only agonists.
- ★Not FDA approved as of this writing; in clinical trials.
Common Questions
1. What three receptors does retatrutide target, and which adds the energy-expenditure effect?
2. Why does retatrutide produce more heart-rate elevation than semaglutide?
3. What tracking variables matter most for monitoring a triple agonist?
Track Your Protocol
Download Dosed for smart reminders, injection tracking, and protocol history.
Download DosedFAQs
Common questions about this topic
No. As of this writing, retatrutide is investigational and not FDA approved. It is available only through clinical trials enrolled by Eli Lilly and approved investigator sites. Approval is anticipated within the next several years pending Phase 3 trial completion and FDA review. Researchers using retatrutide-labeled research peptides outside of trial settings should understand the regulatory and safety implications.
Tirzepatide (GLP-1 + GIP) and retatrutide (adds glucagon) share GI side effects (nausea, vomiting) and appetite suppression. Retatrutide adds slightly more pronounced heart-rate elevation, somewhat more fatigue at higher doses, and the unique signature of increased resting energy expenditure. In trials, GI side effects were broadly comparable.
In published trials retatrutide showed glucose-dependent insulin secretion (via the GIP arm) similar to other dual-agonist peptides. Significant hypoglycemia in monotherapy non-diabetic subjects is uncommon. Risk is higher when combined with insulin or sulfonylureas, which would not typically apply in research contexts. Personal monitoring of blood glucose is sensible during dose escalation.
In published trials, dose increments were spaced out (often every 2-4 weeks) to let side effects from each step settle before the next. The pace that applies to any individual is set by their protocol and prescriber, not by this page. Dosed simply records whichever steps and timing have been set, alongside the side effects logged at each one.
Yes. Dosed supports researcher-managed tracking of investigational peptide protocols. Log dose, site, weight, vitals, and side effects; the app produces trend visualizations, side-effect heat maps, and reconstitution calculators. Dose-escalation schedules can be templated based on published trial protocols. This content is for educational and research-tracking purposes only and does not constitute medical advice.